Search

Your search keyword '"Smichkoska, Snezhana"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Smichkoska, Snezhana" Remove constraint Author: "Smichkoska, Snezhana"
45 results on '"Smichkoska, Snezhana"'

Search Results

1. Real-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast cancer

2. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

3. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

4. How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement

5. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

6. Dosimetric comparison of two-dimensional versus three-dimensional intracavitary brachytherapy in locally advanced cervical cancer

7. Impact on radiation dose and volume V57 Gy of the brain on recurrence and survival of patients with glioblastoma multiformae

9. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

10. Two truncating variants in FANCC and breast cancer risk

12. The highest frequency of c.3700_3704del detected among Albanians from Kosovo

13. Additional file 4 of Common variants in breast cancer risk loci predispose to distinct tumor subtypes

15. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

16. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

17. The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo.

18. How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement

19. Common breast cancer risk loci predispose to distinct tumor subtypes

20. Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes

22. Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe

24. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

25. Expenditures on Oncology Drugs and Cancer Mortality‐to‐Incidence Ratio in Central and Eastern Europe.

26. Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement

28. <italic>BRCA1</italic> and <italic>BRCA2</italic> germline variants in breast cancer patients from the Republic of Macedonia.

29. Režimi alteriranog frakcioniranja u primarnoj radioterapiji kod planocelularnog karcinoma larinksa, orofarinksa i hipofarinksa - analiza prognostičkih faktora lokoregionalne kontrole i preživljavanja

31. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

32. Two truncating variants in FANCC and breast cancer risk

33. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

34. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

35. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

36. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

37. Additional file 2 of Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

38. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

39. Additional file 2 of Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

40. Two truncating variants in FANCC and breast cancer risk

41. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

42. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.

43. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.

44. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

45. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases.

Catalog

Books, media, physical & digital resources